Regulus Therapeutics (NASDAQ: RGLS)
Regulus Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Regulus Therapeutics Company Info
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.
News & Analysis
Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied?
Another case of jaundice for RG-101.
Can These Upstarts Knock Gilead Sciences Off Its Perch?
Achlllion Pharmaceuticals and Regulus Therapeutics have set their sights on the highly lucrative hepatitis C market.
Why Regulus Therapeutics Inc. Fell 20.1% in April
Adverse events might sink the first candidate from an otherwise interesting platform.
Why Regulus Therapeutics Is Slumping 14% Today
Updated results for its clinical-stage hepatitis C drug failed to spark a rally.
Is This the Company Gilead Sciences Should Fear Most? (Hint: It's Not Merck or AbbVie)
A novel new hepatitis C drug under development at Regulus Therapeutics just put up impressive mid stage interim trial results.
Why Shares of Regulus Therapeutics Skyrocketed Higher Today
The biopharma may have just hit pay dirt with its experimental hepatitis C treatment.
Why Regulus Therapeutics Inc. Shares Soared Higher Today
AstraZeneca Plc Inc is advancing Regulus Therapeutics' RG-125 into human trials.
2 Small Biotech Stocks Dreaming Big in Hepatitis C
Exciting but speculative -- Industry Focus examines two companies making strides in the treatment of hepatitis C.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.